# OnCo record nct03778229 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03778229/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03778229", "NCT03778229" ;
  schema:name "Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib"@en ;
  schema:alternateName "SAVANNAH"@en ;
  schema:description "A phase 2 trial of Osimertinib and Savolitinib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03778229/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03778229> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2019-01-09" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/>, <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/met-altered-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/savolitinib/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/hutchmed/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct03778229-ann-oncol-2025/> .